Objective: To determine the most discriminating two-dimensional gray-scale and colour Doppler sonographic features that allow differentiation between malignant and benign adnexal masses, and to develop a scoring model that would enable more accurate diagnosis with those features. Methods: A cross sectional prospective study was conducted on patients scheduled for surgery due to presence of adnexal masses at Woman’s Health Center, Assiut University, Egypt between October 2012 and October 2013. All patients were evaluated by 2D ultrasound for morphological features of the masses combined with colour Doppler examination of their vessels. The final diagnosis, based on histopathological analysis, was used as a gold standard. Results: One hundred forty-six patients were recruited, 104 with benign masses, 42 with malignant masses. Features that allowed statistically significant discrimination of benignity from malignancy were; volume of mass, type of mass, presence and thickness of septae, presence and length of papillary projections, location of vessels at colour Doppler and colour score. A scoring model was formulated combining these features together; Assiut Scoring Model (ASM). The cut-off level with the highest accuracy in detection of malignancy, was ≥6, had a sensitivity of 93.5% and specificity of 92.2%. Conclusion: Our Scoring Model; a multiparameter scoring using four gray-scale ultrasound and two colour Doppler features, had shown a high sensitivity and specificity for prediction of malignancy in adnexal masses compared with previous scoring systems.

Objective: To determine the most discriminating two-dimensional gray-scale and colour Doppler sonographic features that allow differentiation between malignant and benign adnexal masses, and to develop a scoring model that would enable more accurate diagnosis with those features. Methods: A cross sectional prospective study was conducted on patients scheduled for surgery due to presence of adnexal masses at Woman’s Health Center, Assiut University, Egypt between October 2012 and October 2013. All patients were evaluated by 2D ultrasound for morphological features of the masses combined with colour Doppler examination of their vessels. The final diagnosis, based on histopathological analysis, was used as a gold standard. Results: One hundred forty-six patients were recruited, 104 with benign masses, 42 with malignant masses. Features that allowed statistically significant discrimination of benignity from malignancy were; volume of mass, type of mass, presence and thickness of septae, presence and length of papillary projections, location of vessels at colour Doppler and colour score. A scoring model was formulated combining these features together; Assiut Scoring Model (ASM). The cut-off level with the highest accuracy in detection of malignancy, was ≥6, had a sensitivity of 93.5% and specificity of 92.2%. Conclusion: Our Scoring Model; a multiparameter scoring using four gray-scale ultrasound and two colour Doppler features, had shown a high sensitivity and specificity for prediction of malignancy in adnexal masses compared with previous scoring systems.

مازال الاختلاف قائما حول كيفية علاج الكسور الغير ثابتة لمدور عظمة الفخذ. وكان من المعتاد استخدام مسمار الحوض الديناميكي في علاج مثل هذه الكسور. منذ وقت قريب بدأ بعض الجراحين باستخدام الاستبدال النصفي لمفصل الحوض في علاج الكسور الغير ثابتة لمدور عظمة الفخذ لأنه يؤدي الى نتائج وظيفية أفضل و يحد من المضاعفات.

مازال الاختلاف قائما حول كيفية علاج الكسور الغير ثابتة لمدور عظمة الفخذ. وكان من المعتاد استخدام مسمار الحوض الديناميكي في علاج مثل هذه الكسور. منذ وقت قريب بدأ بعض الجراحين باستخدام الاستبدال النصفي لمفصل الحوض في علاج الكسور الغير ثابتة لمدور عظمة الفخذ لأنه يؤدي الى نتائج وظيفية أفضل و يحد من المضاعفات.

مازال الاختلاف قائما حول كيفية علاج الكسور الغير ثابتة لمدور عظمة الفخذ. وكان من المعتاد استخدام مسمار الحوض الديناميكي في علاج مثل هذه الكسور. منذ وقت قريب بدأ بعض الجراحين باستخدام الاستبدال النصفي لمفصل الحوض في علاج الكسور الغير ثابتة لمدور عظمة الفخذ لأنه يؤدي الى نتائج وظيفية أفضل و يحد من المضاعفات.

مازال الاختلاف قائما حول كيفية علاج الكسور الغير ثابتة لمدور عظمة الفخذ. وكان من المعتاد استخدام مسمار الحوض الديناميكي في علاج مثل هذه الكسور. منذ وقت قريب بدأ بعض الجراحين باستخدام الاستبدال النصفي لمفصل الحوض في علاج الكسور الغير ثابتة لمدور عظمة الفخذ لأنه يؤدي الى نتائج وظيفية أفضل و يحد من المضاعفات.

مازال الاختلاف قائما حول كيفية علاج الكسور الغير ثابتة لمدور عظمة الفخذ. وكان من المعتاد استخدام مسمار الحوض الديناميكي في علاج مثل هذه الكسور. منذ وقت قريب بدأ بعض الجراحين باستخدام الاستبدال النصفي لمفصل الحوض في علاج الكسور الغير ثابتة لمدور عظمة الفخذ لأنه يؤدي الى نتائج وظيفية أفضل و يحد من المضاعفات.

Background Increased matrix metalloproteinase (MMP) activity in the endometrium is a predisposing factor for bleeding with depot medroxy progesterone acetate (DMPA) injectable contraception. Doxycycline (DOX) has been proven in vitro to inhibit MMP-mediated degradation of stromal matrix. The current study examined the effect of DOX compared to placebo in treating a current bleeding episode during DMPA use. Study Design A double-blinded randomized controlled trial was conducted in Assiut, Egypt. DMPA users with current bleeding episode were counseled to participate. Women who agreed to participate were randomly assigned to receive 100 mg DOX twice daily for 5 days (34 patients) or an identical placebo (34 patients). All participants were asked to report bleeding and spotting days in a menstrual diary. All participants were followed for 3 months after treatment. This trial was registered (NCT01254799). Results The relative risk to stop a bleeding episode within 10 days of starting treatment was 0.88 (confidence interval 0.64–1.21) in the treatment group compared to the control. DOX treatment caused no significant difference compared to placebo in the number of bleeding and/or spotting days in the 3 months following the treatment. Conclusion Doxycycline as MMP inhibitor is not effective in stopping a current attack of bleeding with DMPA. It also does not improve the bleeding characteristics of women for the subsequent 3 months following the treatment.